HUMANIGEN, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0002 USD | -97.01% |
|
+19,900.00% | -83.33% |
| 04-12 | Combined Liquidation Plan and Disclosure Statement Filed by Humanigen, Inc. | CI |
| 03-08 | Final DIP Financing Approved for Humanigen, Inc. | CI |
| Sales 2021 | 3.6 287.79 | Sales 2022 | 2.51 201.25 | Capitalization | 14.29M 1.14B |
|---|---|---|---|---|---|
| Net income 2021 | -237M -18.97B | Net income 2022 | -70M -5.6B | EV / Sales 2021 | 53,517,059 x |
| Net cash position 2021 | 45.01M 3.6B | Net cash position 2022 | 10.16M 813M | EV / Sales 2022 | 1,644,636 x |
| P/E ratio 2021 |
-0.92
x | P/E ratio 2022 |
-0.15
x | Employees | 6 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 89.65% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -97.01% | ||
| 1 month | -33.33% | ||
| 3 months | +100.00% | ||
| 6 months | -90.00% | ||
| Current year | -83.33% |
1 week
0.00
0.00
1 month
0.000.00
Current year
0.000.00
1 year
0.000.21
3 years
0.0023.53
5 years
0.0033.95
10 years
0.00229.10
| Managers | Title | Age | Since |
|---|---|---|---|
Cameron Durrant
CEO | Chief Executive Officer | 63 | 06/01/16 |
Omar Ahmed
CTO | Chief Tech/Sci/R&D Officer | - | - |
Dale B. Chappell
CTO | Chief Tech/Sci/R&D Officer | 53 | 05/07/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cameron Durrant
CEO | Chief Executive Officer | 63 | 06/01/16 |
Dale B. Chappell
CTO | Chief Tech/Sci/R&D Officer | 53 | 05/07/20 |
Ronald Barliant
BRD | Director/Board Member | 78 | 06/01/16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.0002 | +19,900.00% | 48,522 |
| 19/04/24 | 0.000001 | 0.00% | 59,800 |
| 18/04/24 | 0.000001 | -99.97% | 18,442 |
Delayed Quote OTC Markets, April 26, 2024 at 07:34 pm
More quotes
Humanigen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing its portfolio of proprietary Humaneered anti-inflammatory immunology and immuno-oncology monoclonal antibodies. Its Humaneered technology platform is a method for converting existing antibodies (typically murine) into engineered, high-affinity human antibodies designed for therapeutic use, particularly with acute and chronic conditions. Its product candidate, lenzilumab, and its other product candidate, ifabotuzumab (iFab), are Humaneered monoclonal antibodies are Humaneered monoclonal antibodies. lenzilumab is used as a therapeutic for chronic myelomonocytic leukemia; for the prevention of acute graft versus host disease; and as a prophylactic companion for certain chimeric antigen receptor therapy (CAR-T) programs. The Company has developed or in-licensed targets or research antibodies, typically from academic institutions, and then applied its Humaneered technology to optimize them.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -83.33% | 23.82K | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- HGENQ Stock
